SULOCTIDIL HYDROCHLORIDE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C20H35NOS.ClH
Molecular Weight	374.024
Optical Activity	( + / - )
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCCCCCCCN[C@@H](C)[C@H](O)C1=CC=C(SC(C)C)C=C1

InChI

InChIKey=JRJJHIUHSILDOH-ZHXLSBKVSA-N

InChI=1S/C20H35NOS.ClH/c1-5-6-7-8-9-10-15-21-17(4)20(22)18-11-13-19(14-12-18)23-16(2)3;/h11-14,16-17,20-22H,5-10,15H2,1-4H3;1H/t17-,20-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C20H35NOS
Molecular Weight	337.563
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3466.1986.tb00494.x/full | https://www.ncbi.nlm.nih.gov/pubmed/2839389

Suloctidil is considered to be calcium antagonist. In addition to its vascular antispasmodic activity, suloctidil affects blood platelets and enhances brain energy metabolism. Suloctidil was being evaluated in many clinical trials for use in dementia and thrombotic disorders. Suloctidil induces hepatotoxicity.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
calcium channel activity 11 Target ID: GO:0005262 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6324812 \| https://www.ncbi.nlm.nih.gov/pubmed/3030204	Blocker 555	0.45 µM [Ki]
platelet aggregation 80 Target ID: GO:0070527 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1265708 \| https://www.ncbi.nlm.nih.gov/pubmed/3023210	Inhibitor 8504
Sphingomyelin phosphodiesterase 7 Target ID: CHEMBL2760 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18027916	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Stroke 144 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2988158	Primary	Withdrawn	Unknown Approved Use Unknown
Dementia 27 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14591143	Primary	Withdrawn	Unknown Approved Use Unknown
Candida infections 20 Sources: https://www.ncbi.nlm.nih.gov/pubmed/29050256	Curative	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis.	2013-02	23243064
Combining chemical genomics screens in yeast to reveal spectrum of effects of chemical inhibition of sphingolipid biosynthesis.	2009-01-14	19144191
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.	2008-01-24	18027916
A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor.	2004-02-15	14709594

Patents

Sample Use Guides

In Vivo Use Guide

200 mg t.i.d.

Route of Administration: Oral

In Vitro Use Guide

Suloctidil (10 microM) stimulated the release of prostacyclin (PGI2) from the rabbit aorta, the dog vena cava and the dog portal vein, in vitro.

Substance Class	Chemical Created by `admin` on `Tue Apr 01 17:11:12 GMT 2025` Edited by `admin` on `Tue Apr 01 17:11:12 GMT 2025`
Record UNII	023PF1WLOF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SULOCTIDIL HYDROCHLORIDE

Common Name

English

BENZENEMETHANOL, 4-((1-METHYLETHYL)THIO)-.ALPHA.-(1-(OCTYLAMINO)ETHYL)-, HYDROCHLORIDE, (R*,S*)-

Preferred Name

English

Code System Code Type Description

PUBCHEM

44153242